Clinical Trial Update: A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ritlecitinib for severe alopecia areata in children aged 6 to under 12 has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• Ritlecitinib (ritlecitinib)

Snippet

Sponsor: Pfizer | Conditions: Alopecia Areata | Phase 1 | Status: COMPLETED | Results posted: 2024-10-08